20 results about "Cell binding" patented technology

The application provides a manufacturing method of a near-infrared light responsive gold nano coating intelligent cell culture container, and solves the problems of complex manufacturing process, long cycle, high cost, low efficiency, poor biocompatibility and poor stability of the existing near-infrared light responsive cell culture container. The hydrophilic treatment of the cell culture container (substrate) can increase the number of hydroxyl groups on the surface, thereby increasing the bonding force between the gold nano structure sputtering layer and the cell culture container, making it more stable. The methoxy polyethylene glycol thiol is used to make the gold nano structure polyethylene glycol, so that the PEG is fully combined with the gold nano structure through the mercapto-gold bond to enhance the biocompatibility. Then the polyethylene glycolated gold nano structure and the polypeptide solution are mixed, the concentration of RGD is controlled to make it as much as possible to be coupled with the gold nano structure, and the targeting of the combination with the target cells is enhanced.

This invention relates to the field of biomedical detection technology, specifically disclosing a method for targeted detection of biomimetic nanocarriers based on GPC3 targeting peptides and macrophage membranes. The method includes: S1, acquiring the biomimetic nanocarrier and obtaining particle size distribution data; S2, obtaining nanoparticle morphology images; S3, obtaining characteristic peak signals of surface modification; S4, obtaining cell binding signals; S5, obtaining binding rate data; and S6, plotting release behavior curves. The detection process of this invention integrates multiple physical or chemical properties such as particle size, morphology, cell binding efficiency, and release characteristics. It constructs a multi-dimensional evaluation system using analytical instruments such as DLS, TEM, FTIR, UV-Vis, flow cytometry, and HPLC, overcoming the limitations of traditional detection methods that rely solely on a single indicator (such as particle size or transmission images). This multi-level, multi-angle detection approach makes the assessment of carrier performance more scientific and systematic, exhibiting higher stability and repeatability.

Here are provided advantageous means and methods for assessing target cell killing, i.e. cytotoxicity, e.g. as induced by (engineered) effector cells, such as CAR-T cells, or as induced by effector cells when combined e.g. with an agent, such as an (effector) cell engager, e.g. a bispecific antibody having a binding domain that binds with an effector cell and another binding domain that binds with a target cell. Highly advantageously, an EWOD microfluidic device was found to be useful for accommodating such improved means and methods.

Reagents and methods for preparing nucleic acid samples for sequencing are provided. The reagents include multimeric barcoding reagents that comprise barcode regions linked together and a cell-binding moiety. The methods comprise contacting a nucleic acid sample comprising cells with a library of multimeric barcoding reagents, wherein each multimeric barcoding reagent comprises barcode regions linked together, and appending barcode sequences of a first multimeric barcoding reagent to sub-sequences of a target nucleic acid of a first cell, and appending barcode sequences of a second multimeric barcoding reagent to sub-sequences of a target nucleic acid of a second cell. Methods are also provided that comprise steps of internalising multimeric barcoding reagents into cells (e.g. by endocytosis) or exposing multimeric barcoding reagents to target nucleic acids by lysing cells or permeabilizing cell membranes.

To provide a new polypeptide.SOLUTION: A polypeptide has: a first domain; a linker; and a second domain. The first domain is a domain which has an amino acid sequence where, one or more and four or less amino acid residues may be substituted, depleted, inserted or added from any of multiple specific sequences, or is a domain which has an amino acid sequence which has at least 80% of homology to any of the multiple specific sequences and has enzymatic activity. The linker has a linker having 2 or more and 10 or less amino acid residue length. The second domain is a domain which has an amino acid sequence where, one or more and four or less amino acid residues may be substituted, depleted, inserted or added, from any of other specific sequences, or is a cell binding domain which has an amino acid sequence which has at least 80% of homology to any of other specific sequences.SELECTED DRAWING: Figure 2

The current invention relates to cell-cell interaction and in particular to cellular avidity. Provided are improved means and methods to study cell-cell interaction and characterizing cellular avidity. More in particular, the methods involve studying cell-cell interactions and applying forces in order to break cell-cell bonds in a controllable fashion. Analysing such interactions and breakage of cell bonds in time allows to assess cell-cell binding dynamics.

Disclosed in the present invention are a method for constructing a single cell library containing tissue location information and a sequencing method. The construction method comprises the following steps: S10, providing a chip, wherein the chip is provided with a plurality of sites, each site is provided with nucleic acid molecules having a known base sequence, and the nucleic acid molecules contain location information; S20, enabling a tissue slice to be tested to be in contact with the chip, so as to bind the nucleic acid molecules having the known base sequence in the chip to cells of said tissue slice to obtain a bound tissue slice; S30, dissociating the bound tissue slice to prepare a single cell suspension; S40, constructing a library for the single cell suspension by means of a high-throughput single cell library construction and sequencing platform, to obtain a transcriptome library and a spatial barcoded library; and S50, sequencing the transcriptome library and the spatial barcoded library to obtain a single cell library containing tissue location information. According to the method, spatial location information of a single cell can be tested while analyzing genetic information on a single cell level.

The present application discloses a long-acting heat-stable recombinant human fibronectin and a preparation method thereof, which relates to the technical field of recombinant proteins and aims to solve the technical problem that existing recombinant fibronectin is easily hydrolyzed and inactivated in the skin. The long-acting heat-stable recombinant human fibronectin has an amino acid sequence of the recombinant human fibronectin as shown in SEQ ID No. 3, is derived from natural fibronectin, and contains a human fibronectin binding region as shown in SEQ ID No. 1 and four repeated cell binding regions as shown in SEQ ID No. 2.

The invention relates to the technical field of intelligent cabinets, and discloses an intelligent cabinet article circulation method and device, an intelligent cabinet and a storage medium. The method comprises the following steps: receiving a cell binding request sent by a supervisor; a target cabinet end is determined according to the grid binding request, and when the grid binding result is that grid binding succeeds, if a storage request sent by the target cabinet end is received, an associated article information list is determined according to the storage request; an article scanning code of each article to be transferred is obtained, and when the article scanning code exists in the associated article information list, the target cabinet end is controlled to open a target article storage grid matched with the article scanning code; and when a storage door closing signal of the target storage grid is received, storage completion state information of the to-be-transferred article is generated according to the storage door closing signal and sent to the supervisor, and the storage request is completed until storage completion information corresponding to the storage request is received. According to the invention, the whole-process supervision of the to-be-circulated articles is realized, and the article circulation efficiency is improved.

Cell-binding agents linked to beads are used to attach the beads to cells that are subsequently partitions. Methods, reaction mixtures, and kits as well as other aspects are provided.

Disclosed herein are devices, systems, related methods, computing devices, and computer-readable media relating to cell sorting by embedding using a real-time cell sorter. For example, in some embodiments, a method may include receiving first cell sorter data. A first cell sorter data meter may include cell sorter data including microscope data, hyperspectral imaging data, multispectral data, high dimensional vector data, or one or more combinations thereof. In some embodiments, the cell sorter data may include quantitative fluorescence data representative of one or more antibodies bound per cell, antibody binding capacity (ABC), equivalent soluble fluorescent dye molecules (MESF), one or more other fluorescent quantitative indicators, or one or more combinations thereof. In some embodiments, the quantitative fluorescence data comprises one or more fluorescence signals: one or more fluorescent proteins, one or more fluorescent dyes, one or more fluorescently labeled antibodies, or one or more combinations thereof.

The present invention relates to a switchable chimeric antigen receptor (CAR) comprising a tag or tag-binding domain, which is capable of binding a tag-binding domain or a tag of a targeting module, wherein the targeting module comprises a target cell-binding domain. The invention also relates to a nucleic acid, vector or cell comprising a nucleotide sequence encoding the switchable CAR, a pharmaceutical composition comprising a cell comprising a nucleotide sequence encoding the switchable CAR, a kit and the use as a medicament, in particular for use in the treatment of cancer, infectious disease or autoimmune disease.

The utility model discloses a cell sorter, which belongs to the technical field of magnetic bead type cell sorting and comprises a box body, and the middle of the upper end of the box body is hinged with a baffle plate; the pull rod is fixedly mounted at the upper end of the baffle; the lower end of the box body is fixedly connected with a baseplate; a central control box is fixedly mounted at the outer end of the box body; the magnetic block is fixedly mounted on the inner wall of the left side in the box body; the two partition plates are symmetrically and fixedly installed on the front side and the rear side in the box body, the interior of the box body is divided into a containing bin and a magnetic field separation bin, and a circulating material moving mechanism is installed on the bottom plate. The circulating material moving mechanism comprises a material moving assembly, a synchronous reverse driving assembly and a bearing assembly, and the central control box is electrically connected with the synchronous reverse driving assembly. Through cooperation of the material moving assembly, the synchronous reverse driving assembly and the bearing assembly, magnetic beads and target cells are combined more completely, and the cell sorting efficiency is improved; the interior of the box body is divided into a plurality of chambers by the partition plates, so that test tubes which are not subjected to cell sorting and test tubes subjected to cell sorting in the box body are separated.

The present invention relates to a switchable chimeric antigen receptor (CAR) comprising a tag or tag-binding domain, which is capable of binding a tag-binding domain or a tag of a targeting module, wherein the targeting module comprises a target cell-binding domain. The invention also relates to a nucleic acid, vector or cell comprising a nucleotide sequence encoding the switchable CAR, a pharmaceutical composition comprising a cell comprising a nucleotide sequence encoding the switchable CAR, a kit and the use as a medicament, in particular for use in the treatment of cancer, infectious disease or autoimmune disease.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-human CCR8 monoclonal antibody and a preparation method thereof. The anti-human CCR8 monoclonal antibody of the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO: 1-3; and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO: 4-6. The antibody development process is as follows: Human CCR8 mRNA is synthesized, mice are immunized, and mouse spleen, bone marrow and lymph node cells are collected; a microfluidic droplet sorting system is used to wrap single plasma cell suspension, fluorescently labeled secondary antibody and Human CCR8 HEK293 overexpression cell line in water-in-oil droplets, and dielectrophoresis sorting is performed to enrich plasma cells secreting target cell binding antibodies; single cell library construction is performed on the plasma cells, and NGS sequencing is performed to obtain light and heavy chain naturally paired antibody sequences; the antibody sequences are selected for mammalian cell high-throughput expression, and flow cytometry detection verification is performed. The monoclonal antibody of the application has good antigen-antibody binding activity and specificity at the cell level.

This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.

The invention discloses a construction method and application of a matrigel suppository telocyte immortalized cell line, which comprises the following steps: recruiting in vivo matrigel suppository, sorting telocytes by CD34 immunomagnetic beads, and combining SV40T transduction to establish the telocyte immortalized cell line. And carrying out morphological observation, specific marker detection and functional verification to identify that the obtained cell line is the teterocyte. According to the construction method, the teterocyte closer to the in-vivo functional state can be efficiently obtained, and the obtained cell line can be stably passaged for a long time and maintain the morphological characteristics and biological functions of primary cells; a stable and reliable tool is provided for in-vitro research such as subcutaneous microenvironment research, drug screening and cell therapy, tissue engineering and regenerative medicine and continuous in-depth research in related fields, and the method has wide application value in multiple scientific research fields such as tissue engineering model construction, intercellular interaction research and drug effect evaluation.

The invention relates to biological medicine and nanometer medicine, in particular to a biological logic gating phase change nanometer robot of an analog digital circuit basic element and application of the biological logic gating phase change nanometer robot. In order to overcome the defect that in the prior art, a treatment method for chronic inflammatory bone injury mainly focuses on infection or inflammation control, and lost bone tissue cannot be recovered, the invention provides a bone injury treatment method. The invention discloses a biological logic gating phase change nano-robot for simulating basic elements of a digital circuit. The biological logic gating phase change nano-robot comprises a sensor domain, a processor domain and an effector domain which are composed of peptide motifs and arranged in sequence. The sensor domain is used for identifying and combining with a target cell; the processor domain is used for identifying a surrounding physical environment and performing logic gating phase change according to the surrounding physical environment; the effector domain is used to carry a therapeutic payload.